Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer

Summary

This is a Phase I safety and feasibility study. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed one cycle of therapy (28 days) before the next subject can be treated. Subjects will be treated with i.v. administration of 1 to 3e8 per meter squared RNA CAR T cells three times weekly (M-W-F) for three weeks.

Timeline

Start

2013-07

Primary completion

2015-12

Completion

2017-03

Drugs

Indications